Jack Michael Kelly

Jack M. Kelly is an associate in the firm’s Technology and Life Sciences group and Capital Markets practice. He has a broad corporate practice advising prospective issuers, listed clients and corporate clients on all forms of M&A activity, equity capital markets transactions, general company law as well as corporate governance matters and general public company representation.

Prior to joining Goodwin, he was an associate at Davis, Polk & Wardwell and McCann FitzGerald and spent time on secondment at Morgan Stanley’s EMEA ECM execution team in London.

ECM

• Greencoat Renewables on numerous share placings*
• Millicom on the IPO and London premium listing and subsequent sell-downs of Helios Towers*
• AIM-quoted Mereo Biopharma Group on its Nasdaq IPO*
• Freeline Therapeutics on its Nasdaq IPO*
• Compass Group’s £2 billion cash box placing**
• Informa’s £1 billion dual-tranche cash box placing**
• Aston Martin Lagonda’s rights issue and concurrent placing**
• EverArc Holding’s SPAC IPO and London standard listing and follow-on offerings**
• Underwriting syndicates on various matters, including: the NYSE IPO of Membership Collective Group*, Hammerson’s rights issue, class 1 disposal and related party transactions*, the IPO and London premium listing of Charter Court Financial Services Group*, the aborted IPO and London premium listing of The Multifamily Housing REIT*, the recapitalisation of National Bank of Greece, which comprised a concurrent rights issue and private placement of equity securities and a debt-for-equity exchange offer* and numerous accelerated primary and secondary offerings*

M&A

• Reliance Industries and Reliance Retail Ventures in connection with the sale of minority equity stakes in Reliance Retail Ventures to:
  • Silver Lake Partners for $1 billion*
  • KKR for $750 million*
  • TPG for $250 million*
  • General Atlantic for $500 million*
  • ADIA for $750 million*
  • GIC for $750 million*
  • the Public Investment Fund of Saudi Arabia for $1.3 billion*
• Charles Taylor on its £285 million takeover by Lovell Minnock*
• Natura on its acquisition of The Body Shop from L’Oréal*
• Technip on its $13 billion merger with FMC Technologies and the dual-listing of the equity securities of the merged entity on the NYSE and Euronext Paris*
• Finance Ireland in relation to its 2022 equity investment by PIMCO and M&G*

*includes experience prior to joining Goodwin

**includes experience whilst on secondment at Morgan Stanley